1. Home
  2. GRC vs NTLA Comparison

GRC vs NTLA Comparison

Compare GRC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRC
  • NTLA
  • Stock Information
  • Founded
  • GRC 1933
  • NTLA 2014
  • Country
  • GRC United States
  • NTLA United States
  • Employees
  • GRC N/A
  • NTLA N/A
  • Industry
  • GRC Fluid Controls
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • GRC Industrials
  • NTLA Health Care
  • Exchange
  • GRC Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • GRC 1.0B
  • NTLA 959.4M
  • IPO Year
  • GRC N/A
  • NTLA 2016
  • Fundamental
  • Price
  • GRC $37.60
  • NTLA $9.50
  • Analyst Decision
  • GRC
  • NTLA Buy
  • Analyst Count
  • GRC 0
  • NTLA 17
  • Target Price
  • GRC N/A
  • NTLA $53.00
  • AVG Volume (30 Days)
  • GRC 64.9K
  • NTLA 3.0M
  • Earning Date
  • GRC 02-07-2025
  • NTLA 02-20-2025
  • Dividend Yield
  • GRC 1.97%
  • NTLA N/A
  • EPS Growth
  • GRC 33.88
  • NTLA N/A
  • EPS
  • GRC 1.45
  • NTLA N/A
  • Revenue
  • GRC $657,528,000.00
  • NTLA $43,086,000.00
  • Revenue This Year
  • GRC $1.05
  • NTLA $52.50
  • Revenue Next Year
  • GRC $3.60
  • NTLA $0.42
  • P/E Ratio
  • GRC $25.88
  • NTLA N/A
  • Revenue Growth
  • GRC 1.95
  • NTLA N/A
  • 52 Week Low
  • GRC $30.47
  • NTLA $9.25
  • 52 Week High
  • GRC $43.79
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • GRC 43.39
  • NTLA 27.36
  • Support Level
  • GRC $35.48
  • NTLA $9.25
  • Resistance Level
  • GRC $37.97
  • NTLA $10.39
  • Average True Range (ATR)
  • GRC 0.81
  • NTLA 0.68
  • MACD
  • GRC 0.09
  • NTLA -0.16
  • Stochastic Oscillator
  • GRC 66.30
  • NTLA 6.11

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: